Cooling Mitts, Socks May Ease a Major Chemo Side Effect

WEDNESDAY, Oct. 18, 2017 -- Many cancer drugs can cause debilitating nerve damage as a side effect. But a small study suggests that simple cold wraps to the hands and feet might prevent it. The side effect, known as peripheral neuropathy, damages...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

AbstractIncreases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Chemotherapy-induced peripheral neuropathy (CIPN), which can include both painful and non-painful symptoms, can persist 6  months or longer after the patient’s last chemotherapeutic treatment. These peripheral sensory and motor deficits are poorly treated by our current analgesics with limited ...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
In conclusion, resolution of CIPN requires in vivo education of CD8+ T cells by exposure to cisplatin. Future studies should examine whether ex vivo CD8+ T cell education could be applied as a therapeutic strategy for treating or preventing CIPN in patients.
Source: Pain - Category: Anesthesiology Tags: Research Paper Source Type: research
Conditions:   Gastrointestinal Cancer;   Colorectal Cancer Interventions:   Diagnostic Test: Ultrasound - Serial and Tibial Nerve;   Procedure: Skin Biopsy;   Other: Abbreviated Neurologic Exam;   Other: Blood draw;   Diagnostic Test: Nerve Conduction Study;   Other: QLQ-CIPN20 Questionnaire Administration Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionsICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. PATIENTS AND METHODS: Eligible TCS were
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Abstract 1). Over the years numerous studies have supported the premise that individuals possessing the 'slow acetylator' phenotype are more at risk from developing drug side-effects. Most prominent amongst these reports are those concerned with hepatotoxicity and peripheral neuropathy following treatment with isoniazid, lupus-like symptoms during procainamide therapy and experiencing hypersensitivity reactions to the various sulphonamide derivatives. Similarly, 'slow acetylators' undergoing heavy exposure to arylamines and related carcinogens are more likely to develop bladder cancer. Contrariwise, there appears ...
Source: Xenobiotica - Category: Research Authors: Tags: Xenobiotica Source Type: research
ConclusionThe addition ofweekly carboplatin to neoadjuvant paclitaxel and dd EC leads to a pCR rate comparable to prior studies (54%). However, hematological toxicity and febrile neutropenia rate was unexpectedly high. Future investigations could focus on reversing the sequence, which may lead to better hematological tolerability.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
The objective of this study was to assess the relative contribution of a wider range of risk factors in the development of CIPN.MethodsThis analysis used the 6 ‐month data after starting chemotherapy from a larger prospective observational study on CIPN risk, prevalence, and quality of life. Patients were assessed at recruitment for possible CIPN risk factors, including prior history of neuropathies, current/past infectious diseases; neurotoxic medicatio n history; personal and treatment characteristics; smoking history, alcohol use, and vegetable/fruit intake. Neuropathy was assessed at 6‐months after starting chemoth...
Source: Brain and Behavior - Category: Neurology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8 ;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJC...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer | Cancer & Oncology | General Medicine | Neurology | Peripheral Neuropathy | Study